Source: Arch Therapeutics, Inc.
Patent Describes Use of Self-Assembling Peptidomimetics to
Create Barriers that Prevent Movement of Bodily Fluids and Contaminants,
as well as Other Applications
Arch Therapeutics, Inc. (OTCQB: ARTH)
("Arch" or the "Company"), developer of novel liquid, gel and solid
hemostatic and wound care devices, announced that the U.S. Patent and
Trademark Office has issued a broad method-of-use patent for products
that contain self-assembling peptidomimetics (U.S. Patent number
9,511,113). The patent is assigned to the Massachusetts Institute of
Technology (MIT) and Versitech Limited and is licensed exclusively to
Arch. Arch is developing products that contain self-assembling
materials, such as the AC5™ family of devices, that may provide faster,
safer and improved solutions for surgical, wound and interventional
care. Arch anticipates that this patent will provide further value and
opportunities for its pipeline.
The broad method-of-use claims cover techniques for
preventing the loss or unwanted movement of body fluids through the
application of products that contain peptidomimetics that self-assemble
into barrier structures on tissue. Peptidomimetics, which are synthetic
molecules made at least partially from amino acids that do not occur in
nature, can mimic peptide structure and function, with potentially more
desirable characteristics. Examples of procedures potentially supported
by this intellectual property include the use of hemostatic agents to
limit or stop bleeding, barrier structures that prevent contamination or
infection, sealants to stop leaks, and applications in the wound care
and tissue regeneration space.
Dr. Terrence W. Norchi, President and CEO of Arch
Therapeutics, said, "We are committed to building and enhancing our
portfolio of assets in order to add value to Arch and further protect
our products in development and potential pipeline. This patent may
offer insight into our future products opportunities."
Dr. Norchi continued, "In the meantime, we continue to make
progress with our plans to submit both European and U.S. regulatory
filings for AC5 devices, and there has been no new incremental request
for information since we completed our clinical trial. We continue to
work with our partners to finalize the manufacturing and quality
information necessary to support our regulatory filings. We look forward
to filing a CE Mark as soon as possible, and we are excited about our
recently announced plans and opportunities regarding the U.S. 510(k)
pathway."
The patent is expected to further enhance intellectual
property protection around potential future products in development. It
complements Arch's current intellectual property estate, which includes
patents focused on self-assembling peptides made of amino acids that
occur in nature and a patent covering peptidomimetic
compositions-of-matter.
Arch has filed its own patent applications and, in addition,
has worldwide exclusive rights to certain patents and patent
applications assigned to MIT and Versitech Limited, the technology
transfer company of the University of Hong Kong. The intellectual
property estate either assigned to or exclusively licensed by Arch or
its wholly owned subsidiary, Arch Biosurgery, Inc., includes 45 patents
and pending applications in multiple jurisdictions, including seven
issued patents in the U.S. The applications and rights cover
self-assembling compositions and methods of making and using such
compositions for medical applications, including stopping bleeding;
preventing the movement of bodily fluids, contaminants, etc., within or
on the human body; preventing adhesions; treatment of leaky or damaged
tight junctions; and reinforcement of weak or damaged vessels, such as
aneurysms, with patents covering this technology in the U.S., Israel,
Europe, Japan, Canada, Australia, Hong Kong and China. Additional patent
applications are pending in multiple jurisdictions.
About Arch Therapeutics, Inc.
Arch Therapeutics, Inc. is a medical device company
developing a novel approach to stop bleeding (hemostasis) and control
leaking (sealant) during surgery and trauma care. Arch is developing
products based on an innovative self-assembling peptide technology
platform with the goal of making surgery and interventional care faster
and safer for patients. Arch's flagship development stage product
candidates, known as the AC5 Surgical Hemostatic Device™ and AC5 Topical
Hemostatic Device™, are being designed to achieve hemostasis during
surgical, wound and interventional care.
No comments:
Post a Comment